Updates of incretin‐related drugs for the treatment of type 2 diabetes

Mechanisms of dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide‐1 receptor agonists and glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor dual‐agonist in glycemic control and/or weight loss.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of Cutaneous Immunology and Allergy 2023-02, Vol.14 (2), p.189-192
Hauptverfasser:	Araki, Hirotaka, Matsumura, Takeshi, Furukawa, Noboru, Araki, Eiichi
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Body fat Body mass index Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - drug therapy Diabetes therapy Dipeptidyl peptidase‐4 inhibitors Dipeptidyl-Peptidase IV Inhibitors - pharmacology Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Drug dosages Drug therapy Glucagon Glucagon-Like Peptide-1 Receptor - agonists Glucose Glucose‐dependent insulinotropic polypeptide receptor Graves disease Humans Hypoglycemia Hypoglycemic agents Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use Incretins - pharmacology Incretins - therapeutic use Insulin Kidneys Pharmaceuticals Polypeptides Type 2 diabetes Update
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Mechanisms of dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide‐1 receptor agonists and glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor dual‐agonist in glycemic control and/or weight loss.
ISSN:	2040-1116 2040-1124
DOI:	10.1111/jdi.13945